Recent Announcements

October 2020



DRIVe logo

BARDA seeks abstract submissions for medical countermeasure development through the DRIVe ReDirect Program

Chemical agents are poisonous vapors, aerosols, liquids, and solids that have toxic health effects. Chemical attacks could occur without warning and injury or death often occurs shortly after exposure ...(more)

 

August 2020



DRIVe logo

BARDA establishes four new partnerships to explore innovative vaccine delivery technologies

New vaccine delivery technologies could provide individuals with a broader range of options for immunization, including ones that are easier to use and potentially more effective than traditional vaccination ...(more)

 

June 2020



DRIVe logo

BARDA partners with Colorado State University’s Infectious Disease Research Center (IDRC) to further develop the SolaVAXTM platform to address COVID-19

BARDA is partnering with Colorado State University’s Infectious Disease Research Center (IDRC) to further develop SolaVAXTM. The SolaVAX TM platform uses a proprietary technology to inactivate a virus ...(more)

 


DRIVe logo

BARDA partners with MBio Diagnostics to develop an in vitro point-of-care serology test for the detection of human anti-SARS-CoV-2 antibodies from whole blood samples

BARDA and MBio Diagnostics are committed to a public-private partnership to develop a test for COVID-19. The MBio COVID-19 Serology Test ...(more)

 


DRIVe logo

BARDA and Empatica forge new partnership to develop an early monitoring platform to identify COVID-19 infection

BARDA and Empatica embark on a new partnership to develop and seek U.S. Food and Drug Administration’s Emergency Use Authorization for Aura, a wearable system and algorithm that can ...(more)

 


DRIVe logo

BARDA supports development of two automated antibody tests for COVID-19 by Ortho Clinical Diagnostics

BARDA is pleased to announce a partnership with Ortho Clinical Diagnostics to further develop two automated antibody tests for COVID-19. ...(more)

 


DRIVe logo

BARDA and Immunexpress Inc. expand partnership to evaluate a sepsis host-based laboratory diagnostic to triage COVID-19 patients

BARDA and Immunexpress Inc. are collaborating to determine the risk of sepsis in COVID-19 patients in the hospital emergency department or ICU. These studies will be used to support 510(k) Food and ...(more)

 


DRIVe logo

BARDA DRIVe and Sepsis Alliance to provide educational content on COVID-19 and Sepsis

Sepsis Alliance and BARDA’s Division of Research, Innovation and Ventures (DRIVe) are partnering to provide two high-quality, evidence-based education and training webinars ...(more)

 


DRIVe logo

BARDA, Snapdragon Chemistry Inc., demonstrate deployable domestic manufacturing technology for COVID-19 vaccine component

BARDA and Snapdragon Chemistry Inc. of Waltham, Massachusetts, will work together over the next year to develop and demonstrate an innovative continuous manufacturing platform ...(more)

 


DRIVe logo

Latest BARDA collaboration with OraSure Technologies Inc. aims to develop highly reliable, high-throughput diagnostic test for SARS-CoV-2 antibodies in oral fluids

BARDA and OraSure Technology, Inc. are partnering again, this time on development of an in vitro (laboratory) diagnostic to detect antibodies for the SARS-CoV-2 virus in oral fluids ...(more)

 


DRIVe logo

BARDA partners with Evidation Health to identify COVID-19 infections more quickly in healthcare workers and first responders using self-monitoring and wearable devices

BARDA is pleased to announce a partnership with Evidation Health of San Mateo, California, to monitor healthcare workers and first responders by leveraging de-identified, patient-generated health data...(more)

 


DRIVe logo

BARDA partners with Quidel Corporation to develop one-hour, mobile-integrated multiplex test on Sofia platform to detect SARS-COV-2 plus three additional respiratory viruses

BARDA and Quidel Corporation entered into a partnership to develop a rapid multi-analyte diagnostic test for use on the Sofia 2 assay system to detect the SARS-CoV-2 virus...(more)

 


DRIVe logo

BARDA announces partnership with Siemens Healthineers to develop automated total antibody test for COVID-19

BARDA entered into a partnership with Siemens Healthineers to accelerate development of the SARS-CoV-2 total antibody test. This laboratory-based total antibody test can be used to detect ...(more)

 

May 2020



DRIVe logo

BARDA and VitalConnect partner to monitor nursing home and COVID-19 patients for early indication of patient deterioration

BARDA is partnering with VitalConnect to assess the ability of a wearable device to remotely monitor individuals during the COVID-19 outbreak for changes in health deterioration...(more)

 


DRIVe logo

BARDA Names First DRIVe Director

BARDA is pleased to announce Sandeep Patel, Ph.D. as the first director of the Division of Research, Innovation and Ventures (DRIVe)...(more)

 

April 2020



BARDA logo

BARDA and InBios International, Inc. partner to expedite development for serological tests to identify asymptomatic or recovered cases of COVID-19

BARDA and InBios International, Inc. are collaborating on the rapid development of the SCoV-2 Ab Detect Rapid Test as a point-of-care assay (test) to detect SARS-CoV-2 reactive antibodies in a blood samples...(more)

 


BARDA logo

BARDA announces partnership expansion with Cytovale, Inc. for continued development of Cytovale’s rapid diagnostic system for sepsis as part of COVID-19 pandemic response

BARDA and Cytovale, Inc. are expanding their partnership for additional advanced research and development of a diagnostic system being designed to diagnose sepsis in less than 10 minutes...(more)

 


BARDA logo

BARDA and Tangen Biosciences, Inc. entered into a public-private partnership to develop a rapid diagnostic test for SARS-CoV-2

BARDA and Tangen Biosciences, Inc. entered into a partnership to develop a rapid diagnostic test for use on the Tangen GeneSparkTM molecular diagnostic system to detect the SARS-CoV-2...(more)

 


BARDA logo

BARDA supports Hememics Biotechnologies, Inc to develop a rapid antigen and antibody diagnostic to identify current or past SARS-CoV-2 infections in 60 seconds

BARDA is collaborating with Hememics Biotechnologies, Inc. on the development of a rapid, Bluetooth-connected SARS-CoV-2 diagnostic test. The test is being designed to detect SARS-CoV-2 antigen...(more)

 


BARDA logo

BARDA and Vela Diagnostics USA, Inc. entered into a public-private partnership to develop a rapid diagnostic test for the COVID-19 pandemic

BARDA and Vela Diagnostics USA, Inc. are entering into a partnership to develop a rapid diagnostic test for use on two instrument platforms to aid in the detection of COVID-19 infections...(more)

 


BARDA logo

HHS/BARDA supports DiaSorin, Inc to develop a fully automated serology test to detect novel coronavirus infections

BARDA is collaborating again with DiaSorin, this time to develop a clinical laboratory test to identify people who have been infected with the SARS-COV-2 virus but have recovered...(more)

 


BARDA logo

HHS supports Nanomix, Inc to develop a rapid mobile diagnostic test to detect presence of current or past COVID-19 infection in patients

BARDA has partnered with Nanomix, Inc. on the development of a COVID-19 rapid mobile test to diagnose COVID-19 infections with results in as little as 15 minutes. The test detects the presence of SARS-CoV-2 antigen...(more)

 


BARDA logo

BARDA is partnering with OraSure Technologies Inc. to develop first rapid at-home COVID-19 diagnostic test

BARDA and OraSure Technology, Inc. are working together on the development of a point-of-care (POC) test for SARS-CoV-2 that could bring testing closer...(more)

 


BARDA logo

BARDA supports Luminex Corporation development of a second diagnostic test to detect novel coronavirus infections

BARDA has partnered again with Luminex Corporation, this time on the development of a COVID-19 sample-to-answer diagnostic. The test detects the presence of COVID-19...(more)

 


BARDA logo

BARDA collaborates with GenMark Dx on a rapid diagnostic test to detect COVID-19

BARDA is partnering with GenMark DX to develop an accurate, rapid coronavirus diagnostic for use in clinical and hospital labs. BARDA’s support follows a March 19 decision by the U.S. Food and Drug...(more)

 

March 2020



BARDA logo

BARDA and Luminex Corporation partner to expedite development and EUA clearance for COVID-19 diagnostic test

BARDA and Luminex Corporation are collaborating on rapid development of the diagnostic test called the NxTAG CoV Extended Panel for COVID-19...(more)

 


BARDA logo

HHS, DoD collaborate with Mesa Biotech on rapid diagnostics to detect coronavirus infections

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will provide Mesa...(more)

 


BARDA logo

BARDA partners with Qiagen to develop a rapid COVID-19 diagnostic test

The U.S. Department of Health and Human Services (HHS) will partner with Qiagen LLC of Germantown, Maryland, to accelerate development of a diagnostic test for the 2019 novel coronavirus...(more)

 


BARDA logo

HHS collaborates with DiaSorin Molecular to develop a COVID-19 diagnostic test

The U.S. Department of Health and Human Services (HHS) is supporting the development of a novel coronavirus diagnostic test by DiaSorin Molecular, LLC of Cypress, California...(more)

 


DRIVe Logo

HHS Seeks Abstract Submissions for 2019-nCoV Diagnostics Development

As part of the U.S. government's ongoing public health response to the 2019 novel coronavirus (2019-nCoV), the U.S. Department of Health and Human Services (HHS) today announced the opening of an Easy Broad Agency Announcement (EZ-BAA) for development of 2019-nCoV......(more)

 

January 2020



Rizlab DRIVe Logo

BARDA DRIVe partners with Rizlab Health to enable home-based blood analysis for differentiation of bacterial vs. viral infections

BARDA DRIVe is pleased to announce a partnership with Rizlab Health of New Brunswick, New Jersey, to develop a transformative technology to help diagnose and differentiate viral or bacterial infections prior to symptom onset......(more)

 


GEand DRIVe Logo

BARDA DRIVe partners with GE and The Feinstein Institutes for Medical Research on ultrasound-based pre-symptomatic pathogen exposure detection

BARDA DRIVe is pleased to announce a partnership with GE Research of Niskayuna, New York, and The Feinstein Institutes for Medical Research of Manhasset, New York, to detect pre-symptomatic exposure to viral or bacterial pathogens using ultrasound. ......(more)


 

October 2019



Cytovale and DRIVe Logo

HHS to advance development of Cytovale rapid sepsis diagnostic

To advance the development of a test that may be able to diagnose sepsis in less than 10 minutes, the U.S Department of Health and Human Services (HHS) will partner with Cytovale of San Francisco......(more)

 


Coulter and DRIVe Logo

HHS joins forces with Beckman Coulter on machine-learning algorithm to identify Sepsis

Identifying patients with sepsis in hospital emergency departments, intensive care units and other hospital settings could be done earlier with diagnostic tests based on machine-learning algorithms......(more)

 


RORY STAUNTON and DRIVe Logo

DRIVe and the Rory Staunton Foundation partner to combat maternal sepsis

BARDA DRIVe is teaming up with the Rory Staunton Foundation for Sepsis Prevention to help combat maternal sepsis, one of the leading causes of pregnancy-related deaths......(more)

 

September 2019



98point6 Logo

DRIVe partners with 98point6 on technology for novel telemedicine approaches to treat infectious diseases and improve situational awareness for public health authorities

BARDA DRIVe is partnering with Seattle-based 98point6 to leverage its on-demand primary care smartphone application......(more)

 


Sound Life Sciences Logo

DRIVe partners with Sound Life Sciences for home-based smart speaker respiratory monitoring of patients

BARDA DRIVe is pleased to announce a partnership with Sound Life Sciences (SLS) of Seattle, Washington. The startup company will deploy a contactless motion and respiratory monitoring......(more)

 


DRIVe Logo

HHS expands network of innovation accelerators

Five accelerators selected to speed development of innovative medical products to transform U.S. health security......(more)

 

August 2019



Sonica Logo

BARDA DRIVe partners with Sonica Health on an advanced, bio-integrated sensor system to detect pre-symptomatic pathogen exposure

BARDA DRIVe is pleased to announce a partnership with Sonica Health of Evanston, IL to assess cardiopulmonary health. Sonica’s bio-integrated, wireless sensor technology comprises a thin, soft, electronic system that gently adheres to the skin......(more)

 

July 2019



Inflammatix Logo

DRIVe and Inflammatix partner to develop a host response-based diagnostic to identify and risk-stratify patients suspected of sepsis

BARDA DRIVe is teaming up with Inflammatix, Inc. to advance development of a host-response-based diagnostic (HostDxT™-Sepsis)...(more)

 


UCSD Logo

DRIVe partners with University of California San Diego

BARDA DRIVe is pleased to announce it is partnering with UC San Diego to develop a miniaturized Vagus Sentinel, Magnetometer (VS-M), a low-profile wearable...(more)

 

June 2019



DRIVe D

DRIVe partners with Evidation on using data generated by wearable biomonitoring devices to predict respiratory infections and exposures to pathogens...

BARDA DRIVe is pleased to announce a partnership with Evidation Health of San Mateo, California, to leverage de-identified, patient-generated health data from everyday device......(more)

 


DRIVe D

Join DRIVe's network of accelerators!

BARDA DRIVe seeks to expand our network of innovation accelerators into new areas of the country to support new product development to improve...(more)

 

May 2019



Janus_Science Logo

DRIVe partners with Janus-I Science to develop new diagnostic assay that can identify unknown viral pathogens in patient clinical specimens

BARDA’s DRIVe is partnering with Janus-I Science, Inc., of Vista, California, to develop a diagnostic assay that is capable of identifying unknown infectious disease pathogens in patient specimens. This transformative technology...(more)

 


ENESI Logo

BARDA DRIVe partners with Enesi Pharma to develop a solid dose vaccine delivery technology for easier administration of vaccines

BARDA’s DRIVe is partnering with Enesi Pharma, of Oxford, UK, to develop a transformative vaccine administrative technology. The ImplaVax® formulation and needle-free system enables solid dose implants containing vaccines...(more)

 

March 2019



DRIVe Logo

DRIVe EZ BAA Portal Is Live

The BARDA DRIVe team is pleased to announce that the new, easy-to-use EZ BAA online Portal is now live. This Portal will replace our existing PDF-based process, helping to improve the user experience, data integrity, and...(more)




DRIVe Logo

DRIVe Releases New Award Opportunity

The DRIVe Special Instructions are open now and will close on May 28, 2019. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to review...(more)




Qvella DRIVe Logo

DRIVe partners with Qvella Corporation to develop an mRNA-based assay to rapidly identify infection and septic patients in under 1 hour

The BARDA DRIVe Solving Sepsis initiative is partnering with Qvella Corporation of Carlsbad, California, to develop ground-breaking technology to diagnose...(more)

 

February 2019



Empatica DRIVe Logo

DRIVe partners with Empatica to develop its FDA-cleared Embrace2 smartband technology to predict illness prior to symptom onset

BARDA DRIVe is pleased to announce it is partnering with Empatica of Cambridge, Massachusetts, to apply Empatica's wearable biomonitoring device...(more)




Immune Express DRIVe Logo

DRIVe partners with Immunexpress to develop a medical diagnostic device to rapidly detect sepsis in patients

The DRIVe Solving Sepsis initiative has partnered with Immunexpress of Seattle, Washington, to develop ground-breaking technology that analyzes a patient’s immune system to diagnose...(more)


January 2019



Sepsis Alliance Logo

New Sepsis Institute provides multiplatform sepsis education training programs for healthcare professionals

To educate healthcare providers on recognizing the signs of sepsis across the continuum of care, DRIVe and Sepsis Alliance, one of the nation’s leading sepsis organizations...(more)




Emory Logo

DRIVe teams up with academic research consortium to develop deep learning software to provide early warning of sepsis in patients

The DRIVe Solving Sepsis initiative is partnering with Emory University to further validate an interoperable machine learning software for early prediction of sepsis in hospital intensive...(more)

 



biobeat Logo

DRIVe Partners with Biobeat

DRIVe partners with Biobeat Technologies of Israel to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear...(more)

 

November 2018



CytoVale Logo

DRIVe partners with Cytovale to develop a rapid diagnostic for sepsis

DRIVe is pleased to announce it is now partnering with Cytovale, Inc. of San Francisco to develop new technology...(more)

 



Bullet

HHS is recruiting for a permanent Director to lead the new BARDA Division of Research, Innovation, and Ventures (DRIVe)

BARDA is seeking to recruit an exceptionally talented and forward-looking leader...(more)

 

September 2018



InnaMed Logo

DRIVe awards InnaMed

DRIVe’s Solving Sepsis program is excited to partner with InnaMed of Philadelphia. InnaMed is developing...(more)

 



Prenosis Logo

DRIVe announces its first Solving Sepsis award

The BARDA DRIVe Solving Sepsis program welcomes its first partner, Prenosis of Chicago, IL. Prenosis is developing ...(more)



Spire Logo

DRIVe awards Spire

DRIVe welcomes partner Spire, Inc. of San Francisco. DRIVe is providing research and development funding for the new Spire Health Tag...(more)

 



EnLiSence Logo

DRIVe awards EnLiSense

DRIVe is excited to announce its first Powered by DRIVe Awardee: EnLiSense of Allen, TX. This partnership...(more)

 

2018


Photo of Timothy G. Buchman

Timothy Buchman joins the DRIVe Solving Sepsis team

Timothy G. Buchman, MD has four decades of bedside experience caring for septic patients. He is Professor of Surgery, Anesthesiology...(more)

 



Photo of Steven Simpson

Steven Simpson joins the DRIVe Solving Sepsis team

Steven Q. Simpson, MD is a prominent medical researcher and expert in sepsis....(more)


 



Bullet

DRIVe requests feedback for Incubators

DRIVe is seeking information from industry incubators operated or associated with a pharmaceutical, biotechnology and medical technology companies to help establish DRIVe’s new Fuel Laboratories...(more)

 



Tyler Merkeley Photo

Tyler Merkeley appointed Interim Director of BARDA's DRIVe

This Division will adopt a bold new approach to partnering in order to accelerate life-saving innovation in medical products and...(more)


 



Bullet

Apply now!
DRIVE's EZ-BAA application is streamlined, fast and user-friendly

DRIVe's new application process, called an EZ-BAA, is now open for business! Medical product developers, research teams and...(more)

Twitter Feed